Want to see AU:FRE full AI Analyst Report?
FRE Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume87.61K
Average Volume (3M)91.61K
Market Cap
AU$8.33M
Enterprise ValueAU$11.46
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding287,198,970
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetZero reported debt and negligible financial leverage provide durable financial flexibility. This lowers bankruptcy risk, supports continued R&D and commercialization spending without immediate interest burden, and preserves optionality to raise funds or strike partnerships as needed.
Product-level Gross MarginA ~36% gross margin in 2025 indicates the company’s products can generate healthy unit-level profitability. If revenue stabilizes or grows, this margin provides room to cover fixed costs and move toward operating leverage, making sustainable profitability achievable with scale.
Improving Cash Burn TrendEvidence of a declining cash burn rate between 2023 and 2025 signals improving cost control and operational discipline. While still negative, a smaller outflow extends runway, reduces near-term financing pressure, and is a constructive sign for longer-term cash sustainability if the trend continues.
Bears Say
Highly Volatile RevenueA ~74% revenue collapse in 2025 highlights unstable top-line performance and weak commercial traction. Persistent revenue volatility undermines forecasting, investment planning and partner confidence, making it difficult to scale operations or achieve steady margins necessary for long-term viability.
Consistent Negative Cash GenerationOngoing negative operating and free cash flow demonstrate the business is not self-funding and will need external capital to sustain development and commercialization. Recurrent cash deficits raise dilution and financing risk and constrain strategic investments that drive durable growth.
Deep Negative Profitability And ROEVery large losses and a sharply negative ROE indicate erosion of shareholder equity and poor capital efficiency. Structural unprofitability reduces internal capital generation, increases reliance on external funding, and impairs the company’s ability to reinvest for sustainable long-term growth.
Firebrick Pharma Limited News
FRE FAQ
What was Firebrick Pharma Limited’s price range in the past 12 months?
Firebrick Pharma Limited lowest share price was AU$0.02 and its highest was AU$0.08 in the past 12 months.
What is Firebrick Pharma Limited’s market cap?
Firebrick Pharma Limited’s market cap is AU$8.33M.
When is Firebrick Pharma Limited’s upcoming earnings report date?
Firebrick Pharma Limited’s upcoming earnings report date is Aug 28, 2026 which is tomorrow.
How were Firebrick Pharma Limited’s earnings last quarter?
Firebrick Pharma Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Firebrick Pharma Limited overvalued?
According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued.
Does Firebrick Pharma Limited pay dividends?
Firebrick Pharma Limited does not currently pay dividends.
What is Firebrick Pharma Limited’s EPS estimate?
Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Firebrick Pharma Limited have?
Firebrick Pharma Limited has 287,198,970 shares outstanding.
What happened to Firebrick Pharma Limited’s price movement after its last earnings report?
Firebrick Pharma Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Firebrick Pharma Limited?
Currently, no hedge funds are holding shares in AU:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Firebrick Pharma Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.27%
Trailing 12-Months
Company Description
Firebrick Pharma Limited
Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.
Technical Analysis
Mayne Pharma Group
―
Immuron Limited
―
AdAlta Ltd.
―
IDT Australia Limited
―
Botanix Pharmaceuticals Limited
―